Distinguished in T-Cell Lymphoma

Dr. Caron A. Jacobson

Oncology | Hematology | Hematology Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Distinguished in T-Cell Lymphoma
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Caron Jacobson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Jacobson is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobson is currently accepting new patients.

Her clinical research consists of co-authoring 173 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles and participated in 2 clinical trials in the study of T-Cell Lymphoma.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma
A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel
Study Phase: Phase 1
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Anakinra, Axicabtagene Ciloleucel
Study Phase: Phase 2
A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Utomilumab, Avelumab, PF04518600
Study Phase: Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Study Phase: Phase 1
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drug: Onalespib
Study Phase: Phase 2
View 6 Less Clinical Trials

170 Total Publications

Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.
Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.
Journal: Transplantation and cellular therapy
Published: June 24, 2025
Similar Doctors
Elite in T-Cell Lymphoma
Dr. David C. Fisher
Hematology Oncology | Oncology
Elite in T-Cell Lymphoma
Dr. David C. Fisher
Hematology Oncology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Fisher is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Fisher is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Fisher is currently accepting new patients.

Elite in T-Cell Lymphoma
Dr. Salvia S. Jain
Hematology | Oncology
Elite in T-Cell Lymphoma
Dr. Salvia S. Jain
Hematology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Salvia Jain is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Jain is currently accepting new patients.

Elite in T-Cell Lymphoma
Dr. David M. Weinstock
Oncology
Elite in T-Cell Lymphoma
Dr. David M. Weinstock
Oncology
450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-4245
Languages Spoken:
English
See accepted insurances

David Weinstock is an Oncologist in Boston, Massachusetts. Dr. Weinstock is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Acute Lymphoblastic Leukemia (ALL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacobson's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile